The FDA Just Validated a $1.6 Billion Platform — and the Real Winner Isn’t Pfizer
FDA's May 2026 approval of Veppanu, the first PROTAC drug, validates targeted protein degradation as a platform — and...
Pfizer
Pfizer’s R&D Reset Isn’t a Strategy — It’s a Symptom of Something Bigger
Chris Boshoff's public pivot toward oncology and obesity signals more than a pipeline refresh at Pfizer. Three converging moves...